PUBLICACIONES 

COMO REDACTORA

  1. de Pablo, A., Alonso, R., Ciriza, C., et al. Gastroesophageal reflux and esophageal motility disorder after lung transplant: Influence on the transplanted graft. Transplantation Proceedings. 2021 May. DOI: 10.1016/j.transproceed.2021.03.035.

https://europepmc.org/article/med/33994181

 

  1. Marcos, A., Serra-Majem, L., Pérez-Jiménez, F., Pascual, V., Tinahones, FC., Estruch, R. Moderate Consumption of Beer and Its Effects on Cardiovascular and Metabolic Health: An Updated Review of Recent Scientific Evidence. Nutrients. 2021;13: 879

https://doi.org/10.3390/nu13030879

 

  1. Pons Vilardell, M. Varas, J.P. Gisbert, et al. Ausencia de Interferencia de Almagato en los Resultados de la Prueba de Aliento para el Diagnóstico de Helicobacter Pylori (Estudio Almatest). Gastroenterol. Hepatol. 2020. doi: 10.1016/j.gastrohep.2020.10.016

https://doi.org/10.1016/j.gastrohep.2020.10.016

 

  1. Morillas C., Escalada J., Palomares R., et al. Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program Diabetes Ther. 2019. 2019; 10(5): 1893–1907. doi: 10.1007/s13300-019-0671-x.

https://link.springer.com/article/10.1007/s13300-019-0671-x

 

  1. Manso Sánchez L.M., Moreno Antón F., Izarzugaza Perón Y., et al. Safety of eribulin as third line chemotherapy in HER2 negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019; 25(2): 219-225. doi: 10.1111/tbj.13199.

https://pubmed.ncbi.nlm.nih.gov/30734437/

 

  1. Viñas, M., Maggio, F., D’Anna, N. et al. Meibomian gland dysfunction (MGD), as diagnosed by non-contact infrared Meibography, in dogs with ocular surface disorders (OSD): a retrospective study. BMC Vet Res. 2019; 15: 443. doi: 10.1186/s12917-019-2203-3.

https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-019-2203-3

 

  1. Toledo M, Mazuela G, Mauri J.A. et al. Levels of anger in epilepsy patients treated with eslicarbazepine acetate. Acta Neurol. Scand. 2019

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ane.13099

 

  1. Pérez-López J, Moltó-Abad M, Muñoz-Delgado C, Morales-Conejo M, Ceberio-Hualde L, del Toro M. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Mol Genet Metab. doi:10.1016/j.ymgme.2018.04.013. In press; available online at: https://www.sciencedirect.com/science/article/pii/S1096719218301288

 

  1. Pérez-López J, Morales-Conejo M, López-Rodríguez M, Hermida-Ameijeiras Á, Moltó-Abad M. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis. Mol Genet Metab. 2017; 121(2):138-149. doi: 10.1016/j.ymgme.2017.04.004.

https://www.ncbi.nlm.nih.gov/pubmed/28410878

 

  1. L. López-Estebaranz, P. Herranz-Pinto, B. Dréno, el grupo de dermatólogos expertos en acné. [Consensus-Based Acne Classification System and Treatment Algorithm for Spain]. Actas Dermosifiliogr 2017;108 (2):120-31. doi: 10.1016/j.ad.2016.10.001.

http://www.actasdermo.org/es/consenso-espanol-establecer-una-clasificacion/articulo/S0001731016303313/

 

  1. Delgado JF, Alonso-Pulpón L, Mirabet S, Almenar L, Villa FP, González-Vílchez F, Palomo J, Blasco T, Dolores García-Cosio M, González-Costello J, de la Fuente L, Rábago G, Lage E, Pascual D, Molina BD, Arizón JM, Muñiz J, Crespo-Leiro MG. Cancer Incidence in Heart Transplant Recipients With Previous Neoplasia History. Am J Transplant. 2016 May;16(5):1569-78. doi: 10.1111/ajt.13637

http://onlinelibrary.wiley.com/doi/10.1111/ajt.13637/epdf

 

  1. V. Ortiz-Cabrera, J. Gallego-Merlo, C. Vélez-Monsalve, R. de Nicolas, S. Fontao Mas, C. Ayuso, M.J. Trujillo-Tiebas. Nine-year experience in Gaucher disease diagnosis at the Spanish reference center Fundación Jiménez Díaz. Molecular Genetics and Metabolism Reports. 2016; 9: 79–85.

http:// www.sciencedirect.com/science/article/pii/S2214426916300477

 

  1. Sevilla I., Segura A., Capdevila J., López C., García-Carbonero R., Grande E. on behalf of GETNE (Spanish Group of NeuroEndocrine Tumors). Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer. 2016; 16:858. doi: 10.1186/s12885-016-2901-1

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2901-1

 

  1. Vila, S. Donnay, J. Arena, J. J. Arrizabalaga, J. Pineda, E. Garcia-Fuentes, et al. Iodine status and thyroid function among Spanish schoolchildren aged 6–7 years: the Tirokid study. Br J Nutr.2016 Mar 10:1-9.

http://www.ncbi.nlm.nih.gov/pubmed/?term=26961225

 

  1. Escobar-Barranco JJ, Pina-Marín B, Fernández-Bonet M. Dexamethasone implants in patients with naïve or refractory diffuse diabetic macular edema. 2015;233(3-4):176-85.

http://www.karger.com/Article/Abstract/371770

 

  1. Gutiérrez-Rivas, E., Bautista, J., Vílchez, J.J., Muelas, N., Díaz-Manera, J., Illa, I. et al. Targeted Screening for the Detection of Pompe Disease in Patients with Unclassified Limb-girdle Muscular Dystrophy or Asymptomatic Hyper-CKemia Using Dried Blood: Spanish Cohort. Neuromuscul Disord. 2015 Jul;25(7):548-53.

http://www.ncbi.nlm.nih.gov/pubmed/?term=25998610

 

  1. Bretón Martíınez, J.R., Cánovas Martínez, A. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease, Journal of the Neurological Sciences. 2015; 358: 459–460. doi: 10.1016/j.jns.2015.08.007

http://www.ncbi.nlm.nih.gov/pubmed/?term=26279333

 

  1. Rodríguez A, Rodríguez-Arnao MD, Labarta JI, Martínez-Aedo MJ, Alija M, Díez-López I, et al. [Results after the first year of treatment with recombinant human growth hormone therapy in a group of Spanish children with short stature] Rev Esp Endocrinol Pediatr 2015; 6 (2): 39-50.

http://www.endocrinologiapediatrica.org/modules.php?name=articulos&idarticulo=315&idlangart=EN

 

  1. Pardo J, García-Sobrino T, López-Ferreiro A. Gastrointestinal symptoms in late-onset Pompe disease: Early response to enzyme replacement therapy. J Neurol Sci. 2015 Jun 15; 353(1-2):181-2. doi: 10.1016/j.jns.2015.04.012. Epub 2015 Apr 17.

http://www.ncbi.nlm.nih.gov/pubmed/25911022

 

  1. Pérez-López J., Selva-O’Callaghan A., Grau-Junyent J.M., et al. Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia. Mol Genet Metab. 2015 Apr; 114(4):580-3. doi: 10.1016/j.ymgme.2015.02.004. Epub 2015 Feb 21.

http://www.ncbi.nlm.nih.gov/pubmed/25752415

 

  1. Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. 2014 Sep; 19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153461/pdf/theoncologist_1472.pdf

 

  1. Gimenez S, Armada B, Iturralde Iriso J, Ginel Mendoza L, Fernández-Morales B. Clinical management of patients with hip and knee osteoarthritis: Patient satisfaction with treatment switch. Rheumatol Int. 2014 Jun; 34(6):823-32.

http://www.ncbi.nlm.nih.gov/pubmed/?term=24362751

 

  1. Rodríguez Arnao MD, Rodríguez Sánchez A, García-Rey C, Arroyo Díez FJ, Cañete Estrada R, García Cuartero B, et al. on behalf of the DATAC study group. The DATAC study: a new growth database. Description of the epidemiology, diagnosis and therapeutic attitude in a group of Spanish children with short stature. J Pediatr Endocr Met 2014; 27(11-12):1201-8.

http://www.ncbi.nlm.nih.gov/pubmed/?term=25210749

 

  1. Terán A, Roncero C, Martínez-Raga J, Torrens M, González F and Casas M. Recomendaciones prácticas sobre el uso de Metadona, y Buprenorfina/Naloxona en España. Practice on the use of methadone and buprenorphine/naloxone in Spain. 2013. ISBN: 978-84-695-7104-0.

http://www.actasanitaria.com/referencias/libros/articulo-recomendaciones-practicas-sobre-el-uso-de-metadona-y-buprenorfinanaloxona-en-espana.html

 

  1. Roncero C, Álvarez FJ, Barral C, Gómez-Baeza S, Gonzalvo B, Rodríguez-Cintas L, et al. on behalf of the PROTEUS study investigators. Driving and legal status of Spanish opioid-dependent patients. Subst Abuse Treat Prev Policy. 2013; 8:19. doi: 1186/1747-597X-8-19.

http://www.substanceabusepolicy.com/content/8/1/19

 

  1. Blanco Tarrio E, Gálvez Mateos R, Zamorano Bayarri E, et al. Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting. Clin Drug Investig. 2013; 33:633–645.

Erratum: Clin Drug Investig. 2014; 34 (5):371.

http://link.springer.com/journal/40261/34/5

 

  1. Moráis López, V. Martínez Suárez, J. Dalmau Serra, M.J. Martínez Gómez, L. Peña-Quintana y V. Varea Calderón. Problemas nutricionales percibidos por los pediatras en niños españoles menores de 3 años. Nutr Hosp. 2012; 27(6):2028-2047.

http://www.nutricionhospitalaria.com/pdf/6026.pdf

 

  1. Blanco E, Galvez R, Zamorano E, López V, Pérez M. Prevalencia del dolor neuropático (DN), según DN4, en atención Primaria. Semergen. 2012;38(4):203-210.

Erratum: Semergen 2014; 40 (4):237

http://www.sciencedirect.com/science/article/pii/S1138359314001609

 

  1. Mañas A, Monroy JL, Alia Ramos A, Cano C, López-Gómez V, Masramón X, Pérez M, On behalf of TENOR collaborative study group. Prevalence of Neuropathic Pain in Radiotherapy Oncology Units. Int J Radiat Oncol Biol Phys.2011; 81(2): 511-520. doi: 10.1016/j.ijrobp.2010.05.047.

http://www.ncbi.nlm.nih.gov/pubmed/?term=20832183

 

  1. García de Paredes M, del Moral González F, Martínez del Prado P, Martí Ciriquián J, Enrech Francés S, Cobo M, Esteban-González E, Ortega Granados A, Majem Tarruella M, Cumplido Burón J, Gascó Hernández A, López Miranda E, Ciria Santos J, De Castro J. First evidence of oncologic neuropathic pain prevalence after screening 8,615 cancer patients. Results of the On study. Ann Oncol. 2011; 22(4):924-30.

http://www.ncbi.nlm.nih.gov/pubmed/20926548

 

  1. Sagrario Mayoralas, Salvador Diaz Lobato, Esther Anton, Xavier Ribera, Irune Unzueta. ECME: Epidemiologic study of the characteristics of women with COPD in Spain. Eur Respir J. 2011; 38 (Suppl 55): 4116.

http://erj.ersjournals.com/content/38/Suppl_55/p4116

 

  1. Mañas A, CiriaJP, Fernández MC, Gonzálvez ML, Morillo V, Pérez M, Masramon X and López-Gómez V on behalf of TENOR collaborative study group. Post-hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health. Clin Transl Oncol. 2011; 13(9):656-63.

http://www.ncbi.nlm.nih.gov/pubmed/21865137

 

  1. Barrera-Chacon, JM, Mendez-Suarez JL, Jáuregui-Abrisqueta ML, Palazon R, Barbara-Bataller E, García-Obrero I. Oxycodone improves pain control and quality of life in anticonvulsant-pretreated spinal cord-injured patients with neuropathic pain. Spinal Cord. 2011; 49(1):36-42.

http://www.ncbi.nlm.nih.gov/pubmed?term=20820176

 

  1. Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease: implications for early diagnosis and treatment. Arch Gerontol Geriatr. 2011; 52(1):18-22.

http://www.ncbi.nlm.nih.gov/pubmed?term=19948364

 

  1. Castro, P. Miranda, F. Sánchez-Ballester, D. Arumi, I. Lizarraga, C. Ebel. Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva. Actas Urol Esp. 2011; 35 (2): 73-79. doi: 10.1016/j.acuro.2010.11.011

http://dialnet.unirioja.es/servlet/articulo?codigo=3420773

 

  1. Rodriguez Gonzalez-Moro JM, de Lucas Ramos P, Izquierdo Alonso JL, López-Muñiz Ballesteros B, Antón Díaz E,Ribera X, Martín A. Impact of COPD severity on physical disability and daily living activities: EDIP-EPOC I and EDIP-EPOC II studies. Int J Clin Pract. 2009; 63 (5): 742–750.

Erratum: Int J Clin Pract, January 2010; 64 (2): 277.

http://www3.interscience.wiley.com/cgi-bin/fulltext/123210748/PDFSTART

 

  1. Coromina Sadurni M, Rodie JU, de Montagut LM, Sánchez Autet M. The use of oral contraceptives as a prevention of recurrent premenstrual psychosis. Psychiatry Res. 2009; 170(2-3):290-1.

http://www.ncbi.nlm.nih.gov/pubmed/?term=19836081

 

  1. López-Pousa S1, Bermejo-Pareja F, Frank A, Hernández F, León T, Rejas-Gutiérrez J; ECO. [The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in Spain]. [Article in Spanish] Rev Neurol.2010; 51(10): 577-88.

http://www.revneurol.com/sec/resumen.php?or=pubmed&id=2009562

 

  1. Caballero, L., Bobes, J., Viladarga, I., Rejas, J. [Clinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO study]. Actas Esp Psiquiatr. 2009; 37(1):17-20.

http://www.ncbi.nlm.nih.gov/pubmed/18815907

 

  1. Pena, P., Sancho, J., Rufo, M., Martinez, S., Rejas, J. Driving cost factors in adult outpatients with refractory epilepsy: a daily clinical practice in clinics of neurology in Spain. Epilepsy Res. 2009; 83 (2-3):133-43.

http://www.ncbi.nlm.nih.gov/pubmed/19095410

 

  1. Sevilla C, Esteban J, Alfonso V, González-Adalid M. Donepezilo bucodispersable: ¿Están los cuidadores principales del paciente con enfermedad de Alzheimer (EA) más satisfechos que con la formulación tradicional de donepezilo? Neurol. 2009; 49: 451-457.

http://www.ncbi.nlm.nih.gov/pubmed/19859884

 

  1. Sevilla C, Jiménez Caballero PE, Alfonso V, González-Adalid M. Current Treatments of Alzheimer Disease: Are Main Caregivers Satisfied with the Drug Treatments Received by Their Patients? Dement Geriatr Cogn Disord 2009; 28:196–205.

http://www.ncbi.nlm.nih.gov/pubmed/19738386

 

  1. Rufo M, Sancho J, Peña P, Masramon X y Rejas J, en nombre del grupo de colaboradores del estudio LINCE. Pautas Terapéuticas en el Paciente con Epilepsia Fármaco-Resistente en Consultas Ambulatorias de Neurología y Epilepsia en España. Neurol. 2008; 46(10): 517-524.

http://www.neurologia.com/sec/resumen.php?or=web&i=e&id=2008409

 

  1. Linazasoro, G. Diagnóstico inicial de la enfermedad de Parkinson: dudas y certezas. Curr Opin Neurol. 2007; 20 (Supl.1): S3-S10.

 

  1. Grandas F. Pródromos y síntomas promotores de la enfermedad de Parkinson. Curr Opin Neurol. 2007; 20 (Supl. 1): S11-S14.

 

  1. Valente, E.M. Avances en la investigación genética de la enfermedad de Parkinson. Curr Opin Neurol. 2007; 20 (Supl. 1): S15-S25.

 

  1. Martí M.J. Alteraciones complejas de la conducta asociadas al tratamiento dopaminérgico crónico. Curr Opin Neurol. 2007; 20 (Supl. 1): S26-S32.

 

  1. García Ruiz-Espiga, P.J. Neurofarmacología clínica de agonistas dopaminérgicos: nuevas perspectivas. Curr Opin Neurol. 2007; 20 (Supl. 1): S33-S38.

https://www.researchgate.net/profile/Pedro-Garcia-Ruiz-2/publication/235960975_Neurofarmacologia_clinica_de_agonistas_dopaminergicos_Nuevas_perspectivas/links/00463514cbc7981b94000000/Neurofarmacologia-clinica-de-agonistas-dopaminergicos-Nuevas-perspectivas.pdf

 

  1. Winkelmann, J. Síndrome de piernas inquietas: actualización del tratamiento. Curr Opin Neurol. 2007; 20 (Supl. 1): S39-S47.